<DOC>
	<DOC>NCT01056679</DOC>
	<brief_summary>The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.</brief_summary>
	<brief_title>Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Hodgkin Lymphoma, intermediate or advanced stage Age &gt;60 and &lt;75 years ECOG 2 or better No major organ dysfunction Ability to take aspirin or LMW Heparin HL as composite lymphoma Prior use of lenalidomide Prior use of chemo or radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>